RAIN- For a small Bio lets take a peek at some of the faces behind the name> Rain strengthening of the leadership team---> including new VP of Clinical Development Nora Ku (joining from Loxo Oncology at Lilly) and BP Head of Global Drug Safety and Pharmacovigilance Flor Nicolas (joining from Gilead Sciences). Likewise, new VP and Head of Global Regulatory Affairs Tina Kim-Hafken joined from Seagen (served there as Senior Director of Regulatory Affairs). Dr. John Maraganore assuming an advisory role to CEO and Leadership team adds significantly to credibility here (well-known executive for his founding role and serving as CEO at Alnylam Pharmaceuticals for 20 years). As for institutional investors of note, Perceptive Advisors owns a 9.4% stake and Biotechnology Value Fund owns an 18.8% stake. Cormorant Global Healthcare Master Fund owned a 9.99% stake. Of note regarding insiders, CEO Vellanki recently bought 25,000 shares on the open market and owns 2.471 million shares. On the board of directors, we find Aaron Davis (cofounder and CEO of Boxer Capital), Gorjan Hrustanovic (principal at BVF Partners) and Peter Radovich (COO of Core Biotech holding Mirum Pharmaceuticals) CAN THEY ALL BE WRONG-?
Really though Stoney, you gotta learn how these things work. And then apply it to meme stocks. This ASAN traded over 9M shares yesterday, and then they bumped it 24% in the after hours on less than 80K shares. This is what's called EASY MONEY if there are shares available to short. Which in this case there were. VZ SCORES A 20% WINNER STICK WITH THE KING STONEY!
LTH Life Time Group Holdings, Inc. DOWN 10%? $17.48-1.21(-6.47%)11:00 AM 03/08/23 NYSE |$USD |Pre-Market:$16.81-0.67(-3.83%)2:47 AM
I don't do pre market but what! Life Time Group price target raised to $21 from $20 at RBC Capital 08:17 LTH
Aren't you glad I did the work and kept you in? More of today's news... this one written a week ago: ~the king
I'm figuring out there are two Vertex's now-- The one we covered this week and the real one--> Vertex says FDA clears IND for VX-264 with potential to treat type 1 diabetes » 08:09 VRTX Vertex Pharmaceuticals … Vertex says FDA clears IND for VX-264 with potential to treat type 1 diabetes » 08:09 VRTX Vertex Pharmaceuticals …
Confusing! They both have the same parent name!!! A) VRTX- B) VERX Vertex price target raised to $25 from $19 at Needham 07:56 VERX,